- Home
- Publications
- Publication Search
- Publication Details
Title
Molnupiravir: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-20
DOI
10.1007/s40265-022-01684-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
- (2022) Laura Vangeel et al. ANTIVIRAL RESEARCH
- Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
- (2022) Denisa Bojkova et al. CELL RESEARCH
- SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
- (2022) Pengfei Li et al. CELL RESEARCH
- Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19
- (2021) Ilaria Vicenti et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
- (2021) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Letter to the Editor in Response to Zhou et al
- (2021) Sean Troth et al. JOURNAL OF INFECTIOUS DISEASES
- Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
- (2021) Florian Kabinger et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
- (2021) Wendy Holman et al. Trials
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
- (2021) William A. Fischer et al. Science Translational Medicine
- Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
- (2021) George R Painter et al. Current Opinion in Virology
- Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
- (2021) John A. McIntosh et al. ACS Central Science
- Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
- (2021) Ching-Chi Lee et al. Antibiotics-Basel
- Structure of replicating SARS-CoV-2 polymerase
- (2020) Hauke S. Hillen et al. NATURE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Fight against novel coronavirus: A perspective of medicinal chemists
- (2020) Sk Abdul Amin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started